Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies
Open accessThe DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Solid organ transplantation is a curative therapy for hundreds of thousands of patients with end-stage organ failure. However, long-term outcomes have not improved, and nearly half of transplant recipients will lose their allografts by 10 years after transplant. One of the major challenges facing clinical transplantation is antibody-mediated rejection (AMR) caused by anti-donor HLA antibodies. AMR is highly associated with graft loss, but unfortunately there are few efficacious therapies to prevent and reverse AMR. This Review describes the clinical and histological manifestations of AMR, and discusses the immunopathological mechanisms contributing to antibody-mediated allograft injury as well as current and emerging therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morice, M.-C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,033
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074 · cited 1×
“Another BAFF antagonist, atacicept, reduced dnDSA production in a nonhuman primate model of renal transplantation (86), and belimumab, which showed efficacy in systemic lupus erythematosus (87), is being investigated to reduce pretransplant HLA allosensitization (NCT02500251, ClinicalTrials.”
BackgroundSignificance of the Positive Crossmatch Test in Kidney Transplantation
Patel, R., & Terasaki, P. I. (1969) · New England Journal of Medicine · doi:10.1056/nejm196904032801401 · Cited by 1,508 · cited 3×
“The pathogenic role of alloantibodies in solid organ transplantation was recognized in the 1960s, when Patel and Terasaki (2) seminally showed that donor-specific antibodies, detected by cytotoxic crossmatch, were associated with immediate failure of renal allografts.”
BackgroundInfluentialHaas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., van Huyen, J.-P. D., Mooney, N., Suberbielle, C., Frémeaux-Bacchi, V., Méjean, A., Desgrandchamps, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302506 · Cited by 852 · cited 1×
“The prognostic value of these assays remains controversial (5, 7, 20, 49–52), in part because in vitro complement activity appears to be tightly tied to antibody titer (20, 44, 53, 54).”
BackgroundKuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768 · cited 1×
“Proteasome inhibitors such as bortezomib (76) and carfilzomib (77) may more effectively target metabolically active plasma cells.”
BackgroundRituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692 · cited 1×
“Eighty percent of highly sensitized transplant candidates responded to rituximab-based desensitization, enabling transplantation in patients who may otherwise have waited longer and possibly died before receiving an organ (74).”
BackgroundAntibody-Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure
Einecke, G., Sis, B., Reeve, J., Mengel, M., Campbell, P. M., Hidalgo, L. G., Kaplan, B., & Halloran, P. F. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02799.x · Cited by 687
Demetris, A. J., Bellamy, C., Hübscher, S. G., O’Leary, J., Randhawa, P. S., Feng, S., Neil, D., Colvin, R. B., McCaughan, G., Fung, J. J., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13909 · Cited by 650
Berry, G. J., Burke, M. M., Andersen, C. B., Bruneval, P., Fedrigo, M., Fishbein, M. C., Goddard, M. J., Hammond, E. H., Leone, O., Marboe, C. C., et al. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.08.011 · Cited by 633
Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14107 · Cited by 629 · cited 1×
“Thus, the “molecular microscope” may enable pathologists to further distinguish AMR from other forms of allograft injury (152), and facilitate a better understanding of intragraft changes during AMR, but the field awaits confirmation of these studies by other laboratories.”
BackgroundSelf-citationLund, L. H., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Christie, J. D., Dipchand, A. I., Dobbels, F., Goldfarb, S. B., Levvey, B. J., Meiser, B., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.08.003 · Cited by 604 · cited 2×
“TV accounts for one-third of cardiac allograft recipient deaths late after transplant (163).”
BackgroundStegall, M. D., Diwan, T., Raghavaiah, S., Cornell, L. D., Burns, J., Dean, P. G., Cosio, F. G., Gandhi, M. J., Kremers, W., & Gloor, J. M. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03757.x · Cited by 577 · cited 1×
“Eculizumab may facilitate transplantation across high levels of donor-specific antibodies (106) and be effective as salvage therapy for aggressive AMR (107).”
BackgroundCapillary deposition of C4d complement fragment and early renal graft loss
Feucht, H. E., Schneeberger, H., Hillebrand, G., Burkhardt, K., Weiss, M., Riethmüller, G., Land, W., & Albert, E. (1993) · Kidney International · doi:10.1038/ki.1993.187 · Cited by 542
COLLINS, A. B., SCHNEEBERGER, E. E., PASCUAL, M. A., SAIDMAN, S. L., WILLIAMS, W. W., TOLKOFF-RUBIN, N., COSIMI, A. B., & COLVIN, R. B. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10102208 · Cited by 515
Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure
Gaston, R. S., Cecka, J. M., Kasiske, B. L., Fieberg, A. M., Leduc, R., Cosio, F. C., Gourishankar, S., Grande, J., Halloran, P., Hunsicker, L., et al. (2010) · Transplantation · doi:10.1097/tp.0b013e3181e065de · Cited by 493
Levine, D. J., Glanville, A. R., Aboyoun, C., Belperio, J., Benden, C., Berry, G. J., Hachem, R., Hayes, D., Neil, D., Reinsmoen, N. L., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.1223 · Cited by 488 · cited 7×
“100, 118 Yes; required (HLA) Unknown; studies report only for-cause biopsies, since protocol biopsy of this organ is rare Yes; diffuse, >50% portal tract staining microvasculature, with or without sinusoidal or central vein involvement (98, 100) Yes; portal microvascular endothelial hypertrophy, portal capillary and i…”
BackgroundInfluentialSis, B., Jhangri, G. S., Bunnag, S., Allanach, K., Kaplan, B., & Halloran, P. F. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02761.x · Cited by 478 · cited 1×
“Sis and colleagues first reported that rejecting renal transplants exhibit increased expression of endothelial-associated transcripts (149, 150), a finding that has been further substantiated by the same group in cardiac allografts (124, 151).”
ResultIdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel-Rammingen, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 473
Keogh, A., Richardson, M., Ruygrok, P., Spratt, P., Galbraith, A., O’Driscoll, G., Macdonald, P., Esmore, D., Muller, D., & Faddy, S. (2004) · Circulation · doi:10.1161/01.cir.0000136812.90177.94 · Cited by 463
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25034 · Cited by 459 · cited 1×
“Peripheral concentrations of IgG are mostly unaltered in patients after rituximab treatment, despite depletion of more than 95% of circulating B cells (75).”
BackgroundOPTN/SRTR 2015 Annual Data Report: Kidney
Hart, A., Smith, J. M., Skeans, M. A., Gustafson, S. K., Stewart, D. E., Cherikh, W. S., Wainright, J. L., Kucheryavaya, A., Woodbury, M., Snyder, J. J., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14124 · Cited by 445 · cited 1×
“org Volume 127 Number 7 July 2017 2017;101(1):141–149.”
Hidalgo, L. G., Sis, B., Sellares, J., Campbell, P. M., Mengel, M., Einecke, G., Chang, J., & Halloran, P. F. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03201.x · Cited by 428
Stegall, M. D., Gloor, J., Winters, J. L., Moore, S. B., & DeGoey, S. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01178.x · Cited by 428 · cited 1×
“Patients who undergo desensitization have higher rejection rates (79), but long-term outcomes are comparable to those of lower risk patients (80, 81).”
BackgroundIncidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
Everly, M. J., Rebellato, L. M., Haisch, C. E., Ozawa, M., Parker, K., Briley, K. P., Catrou, P. G., Bolin, P., Kendrick, W. T., Kendrick, S. A., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827d62e3 · Cited by 385
Wiebe, C., Gibson, I. W., Blydt‐Hansen, T. D., Pochinco, D., Birk, P. E., Ho, J., Karpinski, M., Goldberg, A. M., Storsley, L. J., Rush, D. N., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13347 · Cited by 382 · cited 6×
“Importantly, patients with subclinical AMR experience faster rates of allograft function decline, higher incidence of transplant vasculopathy (TV), and greater risk of graft loss (6, 21, 43, 160), falling at intermediate risk for graft failure between those without DSAs or dysfunction and those with clinically symptom…”
BackgroundInfluentialColvin, M. M., Cook, J. L., Chang, P., Francis, G., Hsu, D. T., Kiernan, M. S., Kobashigawa, J. A., Lindenfeld, J., Masri, S. C., Miller, D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000093 · Cited by 376 · cited 1×
“Intervention is therefore warranted, particularly when AMR is severe (161), but current therapies do not appear efficacious to improve long-term outcomes.”
BackgroundChoi, J., Aubert, O., Vo, A., Loupy, A., Haas, M., Puliyanda, D., Kim, I., Louie, S., Kang, A., Peng, A., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14228 · Cited by 355
Antibody-mediated vascular rejection of kidney allografts: a population-based study
Lefaucheur, C., Loupy, A., Vernerey, D., Duong-Van-Huyen, J.-P., Suberbielle, C., Anglicheau, D., Vérine, J., Beuscart, T., Nochy, D., Bruneval, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61265-3 · Cited by 340 · cited 1×
“After transplant, DSAs of 2,500–3,000 MFI or above at the time of biopsy-proven rejection are associated with worse long-term outcome (42, 43) and increased incidence of AMR (3).”
BackgroundMoreso, F., Ibernon, M., Gomà, M., Carrera, M., Fulladosa, X., Hueso, M., Gil-Vernet, S., Cruzado, J. M., Torras, J., Grinyó, J. M., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01230.x · Cited by 301 · cited 1×
“first noted subclinical AMR in protocol renal allograft biopsies (156), and subsequently there has been increased appreciation that patients without overt graft dysfunction may exhibit abnormal histology on biopsy of renal (6, 43, 157), cardiac (155, 158), and liver (159) allografts.”
BackgroundSubclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts
Loupy, A., Vernerey, D., Tinel, C., Aubert, O., Duong van Huyen, J.-P., Rabant, M., Verine, J., Nochy, D., Empana, J.-P., Martinez, F., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040399 · Cited by 301 · cited 3×
“first noted subclinical AMR in protocol renal allograft biopsies (156), and subsequently there has been increased appreciation that patients without overt graft dysfunction may exhibit abnormal histology on biopsy of renal (6, 43, 157), cardiac (155, 158), and liver (159) allografts.”
BackgroundSmith, J. D., Banner, N. R., Hamour, I. M., Ozawa, M., Goh, A., Robinson, D., Terasaki, P. I., & Rose, M. L. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03383.x · Cited by 295 · cited 1×
“Post-transplant DSAs are also produced by a significant proportion of heart (9), lung (10), liver (11), and intestinal transplant recipients (12).”
BackgroundIgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Lefaucheur, C., Viglietti, D., Bentlejewski, C., Duong van Huyen, J.-P., Vernerey, D., Aubert, O., Verine, J., Jouven, X., Legendre, C., Glotz, D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111120 · Cited by 292
Molecular Diagnosis of Antibody-Mediated Rejection in Human Kidney Transplants
Sellarés, J., Reeve, J., Loupy, A., Mengel, M., Sis, B., Skene, A., de Freitas, D. G., Kreepala, C., Hidalgo, L. G., Famulski, K. S., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12150 · Cited by 280 · cited 1×
“Sis and colleagues first reported that rejecting renal transplants exhibit increased expression of endothelial-associated transcripts (149, 150), a finding that has been further substantiated by the same group in cardiac allografts (124, 151).”
ResultSicard, A., Ducreux, S., Rabeyrin, M., Couzi, L., McGregor, B., Badet, L., Scoazec, J. Y., Bachelet, T., Lepreux, S., Visentin, J., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101144 · Cited by 276 · cited 4×
“Comoli P, et al. Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients.”
BackgroundInfluentialKaneku, H., O’Leary, J. G., Banuelos, N., Jennings, L. W., Susskind, B. M., Klintmalm, G. B., & Terasaki, P. I. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12212 · Cited by 252 · cited 2×
“Post-transplant DSAs are also produced by a significant proportion of heart (9), lung (10), liver (11), and intestinal transplant recipients (12).”
BackgroundA Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and Alloantibody
Hirohashi, T., Chase, C. M., Della Pelle, P., Sebastian, D., Alessandrini, A., Madsen, J. C., Russell, P. S., & Colvin, R. B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03836.x · Cited by 252 · cited 3×
“This model has identified a key role for NK cells, IFN-γ, and Fas/FasLmediated injury in the process of DSA-induced TV (127, 183).”
BackgroundHISTOLOGICAL FINDINGS IN EARLY ROUTINE BIOPSIES OF STABLE RENAL ALLOGRAFT RECIPIENTS
Rush, D. N., Henry, S. F., Jeffery, J. R., Schroeder, T. J., & Gough, J. (1994) · Transplantation · doi:10.1097/00007890-199401001-00009 · Cited by 250 · cited 1×
“first noted subclinical AMR in protocol renal allograft biopsies (156), and subsequently there has been increased appreciation that patients without overt graft dysfunction may exhibit abnormal histology on biopsy of renal (6, 43, 157), cardiac (155, 158), and liver (159) allografts.”
BackgroundHachem, R. R., Yusen, R. D., Meyers, B. F., Aloush, A. A., Mohanakumar, T., Patterson, G. A., & Trulock, E. P. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.006 · Cited by 235 · cited 1×
“Similarly, chronic damage and TV in heart (25), lung (95, 167, 168), pancreas (169), and liver (11, 28, 170) allografts are more common among patients with a history of biopsy-proven AMR and HLA DSAs.”
BackgroundIntravenous immunoglobulins – understanding properties and mechanisms
Durandy, A., Kaveri, S. V., Kuijpers, T. W., Basta, M., Miescher, S., Ravetch, J. V., & Rieben, R. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.04022.x · Cited by 229 · cited 1×
“immunoglobulin, which has numerous proposed mechanisms of action (72), plasmapheresis can be effective at temporarily reducing circulating HLA antibodies.”
BackgroundZeevi, A., Lunz, J., Feingold, B., Shullo, M., Bermudez, C., Teuteberg, J., & Webber, S. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2012.09.021 · Cited by 210
Chin, C. C., Chen, G., Sequeria, F., Berry, G. J., Siehr, S. L., Bernstein, D., Rosenthal, D. N., Reinhartz, O., & Tyan, D. B. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.08.020 · Cited by 207 · cited 7×
“Claisse G, Absi L, Cognasse F, Alamartine E, Mariat C, Maillard N. Relationship between Mean Fluorescence Intensity and C1q/C3dfixing capacities of anti-HLA antibodies.”
BackgroundInfluentialVo, A. A., Choi, J., Kim, I., Louie, S., Cisneros, K., Kahwaji, J., Toyoda, M., Ge, S., Haas, M., Puliyanda, D., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000741 · Cited by 201 · cited 1×
“org Volume 127 Number 7 July 2017 sitized kidney transplant patients who had failed desensitization with other methods experienced tocilizumab-induced reductions in HLA antibodies that facilitated transplant (88).”
BackgroundPositive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year
Cornell, L. D., Schinstock, C. A., Gandhi, M. J., Kremers, W. K., & Stegall, M. D. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13168 · Cited by 199
Abu-Elmagd, K. M., Wu, G., Costa, G., Lunz, J., Martin, L., Koritsky, D. A., Murase, N., Irish, W., & Zeevi, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04237.x · Cited by 198 · cited 1×
“Intestine No (193) Recommended (35) Unknown; lack of consensus: yes (194), no (195) Recommended (35) Possibly; capillary dilatation and congestion (196) Adherent inflammatory cells in vessels; more severe rejection with transmural inflammation (195, 196) Not well defined because of nonspecific C4d staining and paucity…”
BackgroundRostaing, L., Vincenti, F., Grinyó, J., Rice, K. M., Bresnahan, B., Steinberg, S., Gang, S., Gaite, L. E., Moal, M.-C., Mondragón-Ramirez, G. A., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12460 · Cited by 197 · cited 1×
“Similarly, the CTLA4-Ig fusion protein belatacept reduced the risk of dnDSA formation in low-risk transplant patients (71).”
BackgroundTen-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients
Kobashigawa, J. A., Moriguchi, J. D., Laks, H., Wener, L., Hage, A., Hamilton, M. A., Cogert, G., Marquez, A., Vassilakis, M. E., Patel, J., et al. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.02.009 · Cited by 196 · cited 4×
“CAV appears as arteriosclerotic lesions with inflammatory neointimal hyperplasia that can be clearly distinguished from eccentric atherosclerotic plaques (25).”
BackgroundInfluentialSautenet, B., Blancho, G., Büchler, M., Morelon, E., Toupance, O., Barrou, B., Ducloux, D., Chatelet, V., Moulin, B., Freguin, C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000000958 · Cited by 187
Loupy, A., Duong Van Huyen, J. P., Hidalgo, L., Reeve, J., Racapé, M., Aubert, O., Venner, J. M., Falmuski, K., Bories, M. C., Beuscart, T., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.022907 · Cited by 185
NK Cells Can Trigger Allograft Vasculopathy: The Role of Hybrid Resistance in Solid Organ Allografts
Uehara, S., Chase, C. M., Kitchens, W. H., Rose, H. S., Colvin, R. B., Russell, P. S., & Madsen, J. C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3424 · Cited by 181 · cited 2×
“IFN-γ production by NK cells can be triggered by allogeneic target cells coated with alloantibody (139), and contributes to chronic rejection in murine models (129).”
BackgroundFreitas, M. C. S., Rebellato, L. M., Ozawa, M., Nguyen, A., Sasaki, N., Everly, M., Briley, K. P., Haisch, C. E., Bolin, P., Parker, K., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182888db6 · Cited by 178
HLA Class I Antibody-Mediated Endothelial Cell Proliferation via the mTOR Pathway
Jindra, P. T., Jin, Y.-P., Rozengurt, E., & Reed, E. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2357 · Cited by 173
Self-citationR. Morrell, M., Pilewski, J. M., Gries, C. J., Pipeling, M. R., Crespo, M. M., Ensor, C. R., Yousem, S. A., D’Cunha, J., Shigemura, N., Bermudez, C. A., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.07.018 · Cited by 167
Venner, J. M., Hidalgo, L. G., Famulski, K. S., Chang, J., & Halloran, P. F. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13115 · Cited by 166
Smith, J. D., Hamour, I. M., . Banner, N. R., & Rose, M. L. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01991.x · Cited by 165 · cited 1×
“In vitro assays measure binding of C1q (45) or deposition of C3d (46) or C4d (47, 48) to single-antigen beads, enabling identification of potentially complement-activating antibodies as well as their HLA specificity.”
BackgroundSurvival after Bronchiolitis Obliterans Syndrome among Bilateral Lung Transplant Recipients
Copeland, C., Snyder, L. D., Zaas, D., Turbyfill, W. J., Davis, W. A., & Palmer, S. M. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201002-0211oc · Cited by 160 · cited 1×
“Median survival time of lung allografts after diagnosis of bronchiolitis obliterans syndrome (BOS) is less than 3 years (171).”
BackgroundNon-Complement–Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival
Guidicelli, G., Guerville, F., Lepreux, S., Wiebe, C., Thaunat, O., Dubois, V., Visentin, J., Bachelet, T., Morélon, E., Nickerson, P. W., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040326 · Cited by 160
Clinical role of the renal transplant biopsy
Williams, W. W., Taheri, D., Tolkoff-Rubin, N., & Colvin, R. B. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.213 · Cited by 159 · cited 1×
“For example, transplant glomerulopathy is a feature of chronic AMR in renal allografts, with duplication of the basement membrane in the glomerulus and peritubular capillaries (173).”
BackgroundRoux, A., Lan, I. B. L., Holifanjaniaina, S., Thomas, K. A., Hamid, A. M., Picard, C., Grenet, D., MIRANDA, S. D., Douvry, B., Beaumont, L., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13589 · Cited by 152
Antibody to human leukocyte antigen triggers endothelial exocytosis
Yamakuchi, M., Kirkiles-Smith, N. C., Ferlito, M., Cameron, S. J., Bao, C., Fox-Talbot, K., Wasowska, B. A., Baldwin, W. M., Pober, J. S., & Lowenstein, C. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602035104 · Cited by 152 · cited 3×
“HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs.”
BackgroundPretransplant Risk Assessment in Renal Allograft Recipients Using Virtual Crossmatching
Bielmann, D., Hönger, G., Lutz, D., Mihatsch, M., Steiger, J., & Schaub, S. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01667.x · Cited by 152
Viglietti, D., Loupy, A., Vernerey, D., Bentlejewski, C. A., Gosset, C., Aubert, O., Huyen, J. D. V., Jouven, X., Legendre, C. M., Glotz, D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030368 · Cited by 151
Dong, C., Wilson, J. E., Winters, G. L., & McManus, B. M. (1996) · PubMed · Cited by 150
Prospective Iterative Trial of Proteasome Inhibitor-Based Desensitization
Woodle, E. S., Shields, A. R., Ejaz, N. S., Sadaka, B. H., Girnita, A. L., Walsh, R. C., Alloway, R. R., Brailey, P. A., Cardi, M. A., Jawdeh, B. G. A., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.13050 · Cited by 149 · cited 2×
“Proteasome inhibitors such as bortezomib (76) and carfilzomib (77) may more effectively target metabolically active plasma cells.”
BackgroundKueckelhaus, M., Fischer, S., Seyda, M., Bueno, E. M., Aycart, M. A., Alhefzi, M. M., Elkhal, A., Pomahač, B., & Tullius, S. G. (2015) · Transplant International · doi:10.1111/tri.12652 · Cited by 148 · cited 4×
“An overview of the features of TV across organs and CTA is provided in Table 2.”
BackgroundInfluentialImplications for Human Leukocyte Antigen Antibodies After Lung Transplantation
Snyder, L. D., Wang, Z., Chen, D., Reinsmoen, N. L., Finlen-Copeland, C. A., Davis, W. A., Zaas, D., & Palmer, S. M. (2013) · CHEST Journal · doi:10.1378/chest.12-0587 · Cited by 145
Jane-wit, D., Manes, T. D., Yi, T., Qin, L., Clark, P., Kirkiles-Smith, N. C., Abrahimi, P., Devalliere, J., Moeckel, G., Kulkarni, S., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002972 · Cited by 144
Lúcia, M., Luque, S., Crespo, E., Melilli, E., Cruzado, J. M., Martorell, J., Jarque, M., Gil‐Vernet, S., Manonelles, A., Grinyo, J. M., et al. (2015) · Kidney International · doi:10.1038/ki.2015.205 · Cited by 139 · cited 2×
“This has prompted development of alternative methods to measure alloreactivity, including an HLA-specific B cell enzyme-linked immunospot (ELISPOT) (63, 64), ex vivo stimulation of B cells (65, 66), and staining of peripheral B cells with HLA tetramers (67).”
MethodWozniak, L. J., Hickey, M. J., Venick, R. S., Vargas, J. H., Farmer, D. G., Busuttil, R. W., McDiarmid, S. V., & Reed, E. F. (2015) · Transplantation · doi:10.1097/tp.0000000000000796 · Cited by 139 · cited 1×
“Similarly, chronic damage and TV in heart (25), lung (95, 167, 168), pancreas (169), and liver (11, 28, 170) allografts are more common among patients with a history of biopsy-proven AMR and HLA DSAs.”
BackgroundSelf-citationDrachenberg, C. B., Torrealba, J. R., Nankivell, B. J., Rangel, É. B., Bajema, I. M., Kim, D. U., Arend, L. J., Bracamonte, E. R., Bromberg, J. S., BRUIJN, J. A., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03670.x · Cited by 134 · cited 6×
“Pancreas Yes (32) Yes; required (HLA); “suspicious” if missing Unknown; in ref.”
BackgroundInfluentialJin, Y., Fishbein, M. C., Said, J. W., Jindra, P., Rajalingam, R., Rozengurt, E., & Reed, E. F. (2004) · Human Immunology · doi:10.1016/j.humimm.2004.01.002 · Cited by 132
Self-citationDonor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection
Gunasekaran, M., Xu, Z., Nayak, D. K., Sharma, M., Hachem, R., Walia, R., Bremner, R. M., Smith, M. A., & Mohanakumar, T. (2017) · American Journal of Transplantation · doi:10.1111/ajt.13915 · Cited by 126
Sberro‐Soussan, R., Zuber, J., Suberbielle, C., Candon, S., Martinez, F., Snanoudj, R., Rabant, M., Pallet, N., Nochy, D., Anglicheau, D., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02968.x · Cited by 121 · cited 1×
“HisDSA levels (78), but when bortezomib was combined with plasmapheresis and rituximab, 40% of renal transplant candidates with DSAs were successfully desensitized (76).”
BackgroundNandakumar, K. S., Collin, M., Olsén, A., Nimmerjahn, F., Blom, A. M., Ravetch, J. V., & Holmdahl, R. (2007) · European Journal of Immunology · doi:10.1002/eji.200737581 · Cited by 118
Schinstock, C. A., Cosio, F., Cheungpasitporn, W., Dadhania, D. M., Everly, M. J., Samaniego, M., Cornell, L. D., & Stegall, M. D. (2016) · American Journal of Transplantation · doi:10.1111/ajt.14161 · Cited by 116
Quantifying Renal Allograft Loss Following Early Antibody-Mediated Rejection
Orandi, B. J., Chow, E. K. H., Hsu, A., Gupta, N., Arendonk, K. J. V., Garonzik‐Wang, J., Montgomery, J. R., Wickliffe, C. E., Lonze, B. E., Bagnasco, S. M., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.12982 · Cited by 113 · cited 3×
“Patients treated with plasmapheresis for subclinical AMR had no significant difference in their risk of graft loss at 5 years compared with when subclinical AMR was left untreated (21).”
BackgroundEvidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection
Parkes, M., Halloran, P. F., & Hidalgo, L. G. (2016) · Transplantation · doi:10.1097/tp.0000000000001586 · Cited by 111
Lepin, E. J., Zhang, Q., Zhang, X., Jindra, P. T., Hong, L. S., Ayele, P., Peralta, M. V. P., Gjertson, D. W., Kobashigawa, J. A., Wallace, W. D., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01355.x · Cited by 106 · cited 2×
“Phosphorylation of these signaling molecules has been substantiated in AMR in both mouse and human allografts (102, 147, 148).”
BackgroundSelf-citationJindra, P., Hsueh, A., Hong, L., Gjertson, D. W., Shen, X., GAO, F. G., Dang, J. H. T., Mischel, P. S., Baldwin, W. M., Fishbein, M. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2214 · Cited by 106 · cited 2×
“Activation of these signaling molecules during AMR has been substantiated in vivo in a murine model (147) as well as in human cardiac allografts (101, 102).”
BackgroundSelf-citationComoli, P., Cioni, M., Tagliamacco, A., Quartuccio, G., Innocente, A., Fontana, I., Trivelli, A., Magnasco, A., Nocco, A., Klersy, C., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13700 · Cited by 103 · cited 1×
“The incidence tends to be higher (up to 40%) in pediatric (7, 8) and medicationnonadherent adult transplant patients, with the latter constituting nearly two-thirds of adult transplant patients by 12 years after transplantation (6).”
BackgroundValenzuela, N. M., Mulder, A., & Reed, E. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201434 · Cited by 100
Self-citationAmrouche, L., Aubert, O., Suberbielle, C., Rabant, M., Huyen, J. D. V., Martinez, F., Sberro‐Soussan, R., Scemla, A., Tinel, C., Snanoudj, R., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001650 · Cited by 100
Jin, Y., Valenzuela, N. M., Ziegler, M. E., Rozengurt, E., & Reed, E. F. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12669 · Cited by 97 · cited 3×
“We have proposed that mTOR inhibition may also ameliorate progrowth signaling in the vasculature triggered by HLA antibodies (143).”
BackgroundSelf-citationO’Leary, J. G., Shiller, M. S., Bellamy, C. O. C., Nalesnik, M. A., Kaneku, H., Jennings, L. W., Isse, K., Terasaki, P. I., Klintmalm, G. B., & Demetris, A. J. (2014) · Liver Transplantation · doi:10.1002/lt.23948 · Cited by 97
Lion, J., Taflin, C., Cross, A. R., Robledo-Sarmiento, M., Mariotto, E., Savenay, A., Carmagnat, M., Suberbielle, C., Charron, D. J., Haziot, A., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13644 · Cited by 94 · cited 1×
“Exposure of HLA-DR–expressing endothelial cells increased ERK and Akt phosphorylation (153), as well as activation of proinflammatory Th17 cells (154).”
BackgroundBartlett, A. S., Ramadas, R., Furness, S., Gane, E., & McCall, J. L. (2002) · Liver Transplantation · doi:10.1053/jlts.2002.36240 · Cited by 90 · cited 1×
“first noted subclinical AMR in protocol renal allograft biopsies (156), and subsequently there has been increased appreciation that patients without overt graft dysfunction may exhibit abnormal histology on biopsy of renal (6, 43, 157), cardiac (155, 158), and liver (159) allografts.”
BackgroundBanham, G. D., Prezzi, D., Harford, S. K., Taylor, C. J., Hamer, R., Higgins, R. M., Bradley, J. A., & Clatworthy, M. R. (2013) · Transplantation · doi:10.1097/tp.0b013e318298dd65 · Cited by 83
Narayanan, K., Jaramillo, A., Phelan, D. L., & Mohanakumar, T. (2004) · European Journal of Immunology · doi:10.1002/eji.200324843 · Cited by 83 · cited 1×
“Antibodies, NK cells, and complement likely promote endothelial apoptosis, enhancing leukocyte adhesion, matrix remodeling and fibrosis, and thrombosis (176).”
BackgroundWu, C., Zhao, Y., Xiao, X., Fan, Y., Kloc, M., Liu, W., Ghobrial, R. M., Lan, P., He, X., & Li, X. C. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13808 · Cited by 81 · cited 1×
“Intragraft macrophages have a proinflammatory phenotype during acute rejection, and a repair/ profibrotic phenotype during chronic rejection (137), suggesting that macrophage effector functions differentially contribute to acute and chronic AMR.”
BackgroundPresentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation
Orandi, B. J., Alachkar, N., Kraus, E. S., Naqvi, F. F., Lonze, B. E., Lees, L., Arendonk, K. J. V., Wickliffe, C. E., Bagnasco, S. M., Zachary, A. A., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13434 · Cited by 79
Kohei, N., Tanaka, T., Tanabe, K., Masumori, N., Dvorina, N., Valujskikh, A., Baldwin, W. M., & Fairchild, R. L. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.030 · Cited by 78
Pizzo, H. P., Ettenger, R. B., Gjertson, D. W., Reed, E. F., Zhang, J., Gritsch, H. A., & Chambers, E. T. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3422-5 · Cited by 77 · cited 1×
“Nonadherence to maintenance immunosuppression is an important risk factor for dnDSA production in a number of studies (6, 68), suggesting that T cell inhibition is at least partly efficacious in delaying alloantibody formation.”
BackgroundSelf-citationKaneku, H., O’Leary, J. G., Bañuelos, N., Jennings, L. W., Süßkind, B., Klintmalm, G. B. G., & Terasaki, P. I. (2013) · American Journal of Transplantation · doi:10.1002/ajt.12212 · Cited by 75
Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients
Cheng, E. Y. L., Everly, M. J., Kaneku, H., Bañuelos, N., Wozniak, L. J., Venick, R. S., Marcus, E. A., McDiarmid, S. V., Busuttil, R. W., Terasaki, P. I., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001391 · Cited by 75
Morrell, C. N., Murata, K., Swaim, A. M., Mason, E., Martin, T. V., Thompson, L. E., Ballard, M., Fox-Talbot, K., Wasowska, B. A., & Baldwin, W. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.170332 · Cited by 74 · cited 1×
“Cell surface P-selectin expression by endothelial cells in turn supports adhesion of platelets (133), neutrophils (132), and monocytes (131) in vitro and in vivo, which likely contributes to the infiltration of recipient immune cells.”
BackgroundAllhorn, M., Briceño, J. G., Baudino, L., Lood, C., Olsson, M. L., Izui, S., & Collin, M. (2010) · Blood · doi:10.1182/blood-2009-08-239020 · Cited by 71
Reinsmoen, N. L., Mirocha, J., Ensor, C. R., Marrari, M., Chaux, G. E., Levine, D. J., Zhang, X., & Zeevi, A. (2016) · Transplantation · doi:10.1097/tp.0000000000001389 · Cited by 69
Impact of tofacitinib treatment on human B-cells in vitro and in vivo
Rizzi, M., Lorenzetti, R., Fischer, K., Staniek, J., Janowska, I., Troilo, A., Strohmeier, V., Erlacher, M., Kunze, M., Bannert, B., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.10.005 · Cited by 67 · cited 1×
“One example is JAK3, which is important for activation and Ig production in naive B cells (90).”
BackgroundLood, C., Allhorn, M., Lood, R., Gullstrand, B., Olin, A. I., Rönnblom, L., Truedsson, L., Collin, M., & Bengtsson, A. A. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34454 · Cited by 65
Valenzuela, N. M., Trinh, K. R., Mulder, A., Morrison, S. L., & Reed, E. F. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13174 · Cited by 62
Self-citationYoung, J. S., Chen, J., Miller, M. L., Vu, V., Tian, C., Moon, J. J., Alegre, M.-L., Sciammas, R., & Chong, A. S. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13761 · Cited by 58
Yousem, S. A., & Zeevi, A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825197ae · Cited by 58
Snanoudj, R., Claas, F. H. J., Heidt, S., Legendre, C. M., Chatenoud, L., & Candon, S. (2015) · Kidney International · doi:10.1038/ki.2014.390 · Cited by 57 · cited 1×
“This has prompted development of alternative methods to measure alloreactivity, including an HLA-specific B cell enzyme-linked immunospot (ELISPOT) (63, 64), ex vivo stimulation of B cells (65, 66), and staining of peripheral B cells with HLA tetramers (67).”
MethodSingh, N., Craeyveld, E. V., Tjwa, M., Ciarka, A., Emmerechts, J., Droogné, W., Gordts, S. C., Carlier, V. A., Jacobs, F., Fieuws, S., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.065 · Cited by 57 · cited 4×
“CAV appears as arteriosclerotic lesions with inflammatory neointimal hyperplasia that can be clearly distinguished from eccentric atherosclerotic plaques (25).”
BackgroundInfluentialKhovanova, N. A., Daga, S., Shaikhina, T., Krishnan, N. S., Jones, J., Zehnder, D., Mitchell, D. A., Higgins, R. M., Briggs, D., & Lowe, D. P. (2015) · Transplant International · doi:10.1111/tri.12648 · Cited by 56
Peripheral blood B cells producing donor-specific HLA antibodies in vitro
Han, M., Rogers, J. A., Lavingia, B., & Šťastný, P. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.10.013 · Cited by 56
Sicard, A., Amrouche, L., Suberbielle, C., Carmagnat, M., Candon, S., Thervet, É., Delahousse, M., Legendre, C., Chatenoud, L., & Snanoudj, R. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12512 · Cited by 56 · cited 1×
“Some patients exhibit “natural” or false-positive reactivity with recombinant HLA antigens (61), which do not detrimentally affect allograft outcome (62).”
BackgroundPathologic findings in lung allografts with anti-HLA antibodies
DeNicola, M. M., Weigt, S. S., Belperio, J. A., Reed, E. F., Ross, D. J., & Wallace, W. D. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2012.11.018 · Cited by 55 · cited 2×
“Similarly, chronic damage and TV in heart (25), lung (95, 167, 168), pancreas (169), and liver (11, 28, 170) allografts are more common among patients with a history of biopsy-proven AMR and HLA DSAs.”
BackgroundSelf-citationEvaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
Vincenti, F., Silva, H. T., Busque, S., O’Connell, P. J., Russ, G., Budde, K., Yoshida, A., Tortorici, M. A., Lamba, M., Lawendy, N., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13181 · Cited by 54 · cited 1×
“Although trials of the JAK inhibitor tofacitinib were halted because of adverse events (91), recent reviews have advocated reconsideration of the suitability of this and other JAK inhibitors in maintenance immunosuppression for transplant (92).”
BackgroundAlba, A. C., Tinckam, K. J., Foroutan, F., Nelson, L. M., Gustafsson, F., Sander, K., Brüünsgaard, H., Chih, S., Hayes, H. M., Rao, V., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.11.024 · Cited by 52
Banff study of pathologic changes in lung allograft biopsy specimens with donor-specific antibodies
Wallace, W. D., Li, N., Andersen, C. B., Arrossi, A. V., Askar, M. Z., Berry, G. J., DeNicola, M. M., Neil, D., Pavlisko, E. N., Reed, E. F., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.08.021 · Cited by 46 · cited 7×
“In particular, the intracellular signaling pathways leading to endo- mune factors also contribute to TV, the majority of renal allograft loss due to chronic rejection was associated with HLA DSAs (24, 164).”
BackgroundSelf-citationGalvani, S., Trayssac, M., Augè, N., Thiers, J., Calise, D., Krell, H., Sallusto, F., Kamar, N., Rostaing, L. P. E., Thomsen, M., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.021790 · Cited by 45
Plasma C4d+ Endothelial Microvesicles Increase in Acute Antibody-Mediated Rejection
Tower, C. M., Reyes, M., Nelson, K., Leca, N., Kieran, N. E., Muczynski, K. A., Jefferson, J. A., Blosser, C. D., Kukla, A., MAURER, D. H., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001572 · Cited by 43
Yang, J., Chen, J., Young, J. S., Wang, Q., Yin, D., Sciammas, R., & Chong, A. S. (2016) · Transplantation · doi:10.1097/tp.0000000000001253 · Cited by 38 · cited 1×
“Treatment of mice with cytotoxic T lymphocyte–associated protein-4–Ig (CTLA4-Ig) prevented alloantibody production when given in the first 2 weeks after sensitization (69, 70).”
BackgroundAfzali, B., Chapman, E., Racapé, M., Adam, B., Bruneval, P., Gil, F., Kim, D., Hidalgo, L. G., Campbell, P. M., Sis, B., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13956 · Cited by 37 · cited 1×
“Sis and colleagues first reported that rejecting renal transplants exhibit increased expression of endothelial-associated transcripts (149, 150), a finding that has been further substantiated by the same group in cardiac allografts (124, 151).”
ResultAnti-huCD20 Antibody Therapy for Antibody-Mediated Rejection of Renal Allografts in a Mouse Model
Abe, T., Ishii, D., Gorbacheva, V., Kohei, N., Tsuda, H., Tanaka, T., Dvorina, N., Nonomura, N., Takahara, S., Valujskikh, A., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13150 · Cited by 37 · cited 1×
“Recently, antibody-mediated TV in murine recipients capable of mounting a de novo antibody response against renal allografts was reported (190).”
BackgroundZiegler, M. E., Jin, Y., Young, S. H., Rozengurt, E., & Reed, E. F. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00199.2012 · Cited by 36 · cited 2×
“These signaling pathways promote cytoskeletal rearrangements, as well as increased wound healing and cell growth (143, 145, 146).”
BackgroundSelf-citationRegulation of Anti-HLA Antibody-Dependent Natural Killer Cell Activation by Immunosuppressive Agents
Shin, B., Ge, S., Mirocha, J., Karasyov, A., Vo, A. A., Jordan, S. C., & Toyoda, M. (2013) · Transplantation · doi:10.1097/01.tp.0000438636.52085.50 · Cited by 35 · cited 1×
“Current immunosuppressive drugs incompletely inhibit NK cell–mediated alloreactivity (140).”
BackgroundStojanovic, I. C., Vrtovec, B., Radovančević, B., Radovancevic, R., Yazdanbakhsh, A. P., Thomas, C. D., & Frazier, O. H. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.08.014 · Cited by 34 · cited 4×
“CAV appears as arteriosclerotic lesions with inflammatory neointimal hyperplasia that can be clearly distinguished from eccentric atherosclerotic plaques (25).”
BackgroundInfluentialLin, C. M., Plenter, R. J., Coulombe, M., & Gill, R. G. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13865 · Cited by 34
Li, F., Wei, J., Valenzuela, N. M., Lai, C. K., Zhang, Q., Gjertson, D., Fishbein, M. C., KOBASHIGAWA, J. A., Deng, M. C.-H. K., & Reed, E. F. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.09.047 · Cited by 33 · cited 2×
“Activation of these signaling molecules during AMR has been substantiated in vivo in a murine model (147) as well as in human cardiac allografts (101, 102).”
BackgroundSelf-citationSnanoudj, R., Candon, S., Roelen, D. L., Jaïs, J., Claas, F. H. J., Legendre, C. M., & Chatenoud, L. (2013) · Transplantation · doi:10.1097/01.tp.0000438211.34842.5e · Cited by 31 · cited 1×
“However, given that higher BAFF levels are associated with greater sensitization to HLA (83, 84) and AMR (85), it remains an intriguing therapeutic target in the quest for suppressors of HLA antibody production.”
BackgroundMoore, C. A., Iasella, C. J., Venkataramanan, R., Lakkis, F. G., Smith, R. B., McDyer, J. F., Zeevi, A., & Ensor, C. R. (2016) · Human Immunology · doi:10.1016/j.humimm.2016.12.005 · Cited by 26 · cited 1×
“Although trials of the JAK inhibitor tofacitinib were halted because of adverse events (91), recent reviews have advocated reconsideration of the suitability of this and other JAK inhibitors in maintenance immunosuppression for transplant (92).”
BackgroundClaisse, G., Absi, L., Cognasse, F., Alamartine, É., Mariat, C., & Maillard, N. (2017) · Human Immunology · doi:10.1016/j.humimm.2017.02.003 · Cited by 26
Reyes‐Vargas, E., Pavlov, I. Y., Martins, T. B., Schwartz, J. J., Hill, H. R., & Delgado, J. C. (2009) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.20310 · Cited by 20 · cited 1×
“Endothelial cells exposed to HLA antibodies also elaborate IL-8, TNF-α (181), and VEGF (182), which can signal in an autocrine fashion or act on smooth muscle cells in a paracrine manner.”
BackgroundFrank, R., Dean, S. A., Molina, M. R., Kamoun, M., & Lal, P. (2014) · Cardiovascular Pathology · doi:10.1016/j.carpath.2014.11.001 · Cited by 15 · cited 1×
“org Volume 127 Number 7 July 2017 (119).”
Role of Sphingosine-1-Phosphate in Transplant Vasculopathy Evoked by Anti-HLA Antibody
Trayssac, M., Galvani, S., Augè, N., Sabbadini, R. A., Calise, D., Mucher, E., Sallusto, F., Thomsen, M., Salvayre, R., & Nègre‐Salvayre, A. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13264 · Cited by 14
Viglietti, D., Lefaucheur, C., & Glotz, D. (2016) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000324 · Cited by 14
Cited by
Lefaucheur, C., Viglietti, D., Bouatou, Y., Philippe, A., Pievani, D., Aubert, O., Duong Van Huyen, J.-P., Taupin, J.-L., Glotz, D., Legendre, C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.030 · Cited by 161
The liver as a central "hub" of the immune system: pathophysiological implications
Ronca, V., Gerussi, A., Collins, P., Parente, A., Oo, Y. H., & Invernizzi, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00004.2023 · Cited by 59
Metadata
- Authors
- Valenzuela, N. M., & Reed, E. F.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-12
- Volume
- 127
- Issue
- 7
- Pages
- 2492-2504
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2623050765
- Cited by
- 215
- References
- 128
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.